“…Half of the studies (12 out of 24) used spontaneous reports from the FDA adverse events reporting system (FAERS) database [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ], six from Vigibase [ 26 , 27 , 28 , 29 , 30 , 31 ], three from the French pharmacovigilance database [ 32 , 33 , 34 ], two from the Japanese adverse drug report (JADERS) database [ 35 , 36 ] and one from the Italian spontaneous reporting system [ 37 ]. Bevacizumab was the most studied drug (13 studies) followed by sunitinib (11 studies), sorafenib (10 studies) and axitinib (nine studies).…”